Drug Makers Nervously Eye High Court On Generics

Law360, New York (January 12, 2006, 12:00 AM EST) -- In the shadow of the Supreme Court, the debate over authorized generics is heating up as brand-name drug companies and generic makers prepare to do battle over what they both consider to be their rightful share of the trillion-dollar healthcare industry.

Many generic drug makers are anxiously awaiting news of whether the Supreme Court will rule on the case brought by the Federal Trade Commission against pharmaceutical giant Schering-Plough.

The company stands accused of violating unfair competition laws after it agreed to pay Upsher-Smith Laboratories American...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.